| Trial ID: | L6911 |
| Source ID: | NCT00809705
|
| Associated Drug: |
Placebo
|
| Title: |
A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: Placebo|DRUG: taspoglutide|DRUG: taspoglutide
|
| Outcome Measures: |
Primary: Tmax, log (AUC), log(Cmax)of paracetamol, Days -1, 1, 5, 29, 33, 78 and 82 | Secondary: Adverse events, laboratory parameters, vital signs, Throughout study|renal function (creatinine clearance, urine volume and electrolytes), Throughout study|Multiple dose pharmacokinetics of Taspoglutide, Throughout study
|
| Sponsor/Collaborators: |
Sponsor: Hoffmann-La Roche
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-12
|
| Completion Date: |
2009-10
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-02
|
| Locations: |
Berlin, 14050, Germany|Neuss, 41460, Germany|London, HA1 3UJ, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT00809705
|
